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Abstract 
Background: The new fluoroquinoloneshave demonstrated enhanced activity against the 
most common bacteria involved in lower respiratory tract infection (LRTI). Moxifloxacin is 
the most commonly prescribed respiratory flouroquinolone drug in Yemen. Pneumonia is a 
major and an on-going public health problem globally. With the widely use of 
fluoroquinolones in the clinical practice, the potential for developing resistance has become a 
concern.  
The objectives:The aim of present study was to determine the trend of moxifloxacin 
resistant and the distribution of resistant for different sample types among hospitalised 
patients in Sana'a, Yemen. 
Methods:The study was performed at a private hospital in Sana’a, Yemen. The records were 
taken from the microbiology department for hospitalised patients. Moxifloxacin susceptibility 
samples were collected from January, 2017 to December, 2017. The 
moxifloxacinsusceptibility was studied against several isolates.Full ethical clearance was 
obtained from the qualified authorities who approved the study design. All data were 
analyzed using SPSS Statistics version 21. 
Results: Out of 927 sample isolates, 580 (62.6%) were moxifloxacin resistant isolates and 
only 30.1% were sensitive. The Escherichia coli was observed in 24.4% of total sample 
isolates, followed by Pseudomonas aeruginosa (12.1%). From the study findings, 44.8% of 
total sample was isolated from sputum cultures.There was a statistically significant difference 
between bacteria type and culture results (P-value < 0.001). Moreover, 96.2% of 
Acinetobacter species and all Acinetobacterbaumannii isolates were moxifloxacin resistant. 
The study findings reported that 70.4% of Escherichia coli isolates were resistant for 
moxifloaxin, followed by methicillin resistant staphylococcus aureus (64.7%), Klebsiella 
pneumonia (60.6%), and Pseudomonas aeruginosa (46.4%). However, 86.1% of 
staphylococcus aureus isolates were moxifloxacin resistant. Results in this study showed that 
there was high significantly relationship between culture results and sample type (P-value< 
0.001).  Also 44.8% of sample isolates were from sputum cultures. Moreover, 74.2% of 
sputum cultures isolates were moxifloxacin resistant.There was a statistically significant 
difference between culture results with age groups (P-value = 0.02). Also 64.1% of males had 
moxifloxacin resistant and 36.9% of isolate resistant were aged > 60 years 
Conclusion:This study reveals that varieties of pathogens are responsible for LRTI and 
moxifloxacin resistance has become a great public health issue. The possibility of reducing 
resistance by controlling the use of antibiotics is a reasonable approach. Inappropriate and 
irrational drug usage should be avoided. This study may help the government’s regulatory 
authority to develop a policy about rational prescription of antibiotics to minimize resistance 
of new antibiotics and also to ensure the maximum safety to the health of patients. 
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Introduction: 
The classic fluoroquinolones such as ciprofloxacin, norfloxacin, fleroxacin and 
ofloxacin have had strong activity against Gram-negative bacteria, but the 
effectiveness of these compounds against Gram-positive bacteria has been debated. 
The new fluoroquinolones developed during the 1990s, such as levofloxacin and 
moxifloxacin, have demonstrated enhanced activity against the most common bacteria 
involved in lower respiratory tract infection (LRTI).The mechanism of newer 
fluoroquinolone activity is the inhibition of essential bacterial type II topoisomerases 
(DNA gyrase) and topoisomerase IV
[1]
.All new fluoroquinolones have a bactericidal 
 activity and a post-antibiotic effect. Compared with ciprofloxacin, all new 
fluoroquinolones have a longer elimination half-life that allows once daily dosing. In 
addition, these antibiotics have excellent penetration into respiratory tissues, with the 
highest concentrations found in the epithelial lining fluid and alveolar macrophages
[2]
. 
The newer fluoroquinolonessuch as levofloxacin and moxifloxacin are currently 
availablein both IV and oral formulations. With regard to the pharmacodynamic 
characteristics, the new fluoroquinolones cause concentration-dependent killing
[3]
.  
Moxifloxacin (Avelox; Bayer), a “fourth-generation” fluoroquinolone, is often used in 
the empirical treatment of severe community-acquired pneumonia (CAP), which is 
one of the most common infectious diseases and among the primary causes of death 
worldwide
[4].Streptococcus pneumoniae is the primary pathogen responsible for CAP, 
but many other microorganisms, including Gram-negative and atypical bacteria (e.g., 
Legionella pneumophila, Mycoplasma pneumoniae, andChlamydophilapneumoniae), 
may also be etiological agents
[5]
.The recommended dose of moxifloxacin is 400 
mg/day (q.d.). No dosage adjustment is required in elderly patients, obese patients 
[6]
, 
or patients with renal or mild hepatic impairment 
[7]
. Furthermore, due to the risk of a 
prolonged QT interval (a measure of the time between the start of the Q wave and the 
end of the T wave inthe heart’s electrical cycle), it is recommended that the daily dose 
of moxifloxacin should not exceed 400 mg
[8]
. 
The clinical efficacy of the newer fluoroquinolones in the treatment of LRTI has been 
demonstrated in several randomized, double-blind, prospective studies. In 
comparative community-acquired pneumonia (CAP)studies, newer 
fluoroquinolonesalmost havemore activity than the cephalosporins (e.g. ceftriaxone, 
cefaclor or cefuroxime axetil) and the macrolides (e.g. erythromycin or 
roxithromycin)
[1]
. Niedermanet al.
[9]
 compared hospitalization and mortality in 
patients with CAP being treated with moxifloxacin, amoxicillin or clarithromycin. 
The mortality rate for moxifloxacin-treated patients was significantly better (P = 
0.045) than for comparator-treated patients. Current treatment guidelines for the 
management of LRTI in adults recommend fluoroquinolones for empirical treatment 
in several patient groups. The new fluoroquinolones currently available offer major 
therapeutic advances compared with previous agents, and the incidence of adverse 
events is clearly outweighed by their clinically use
[1]
. As with other antimicrobial, the 
development of resistance is a potential problem associated with their increased use in 
RTIs. Rational prescribing and continous control of antibiotic resistance levels are 
needed to keep their future antibacterial efficacy.The new fluoroquinolones have 
demonstrated enhanced activity against the most common bacteria involved in LRTI. 
Moxifloxacin is the commonly prescribed respiratory flouroquinolone drug in Yemen. 
Pneumonia is a major and an on-going public health problem globally. Thus, the aim 
of present study was to determine the trends of moxifloxacin and the distribution of 
resistant for different sample types among hospitalised patients in Sana'a, Yemen. 
Methods: 
This retrospective study was performed at a private hospital in Sana’a, Yemen. 
Moxifloxacin susceptibility samples were collected from January, 2017 to December, 
2017from the records ofhospitalised patients. The moxifloxacin susceptibility was 
studied against several isolates.Full ethical clearance was obtained from the qualified 
authorities who approved the study design. All data were analyzed using SPSS 
Statistics version 21. 
Results: 
According to the present study, the mean age of study sample (n=927) was 49year 
(with SD ± 21.3 year) and ranged between 1 and 120 years. Out of 927 samples, 580 
 (62.6%) were moxifloxacinresistant isolates and only 30.1% were sensitive.  Also 
(69.0%) of total patients were females and (31.0%) were males. Among 927 of 
patients, (28.2%) was aged between 41- 60 years and 35.5% more than 60 years. The 
Escherichia coli was observed in 24.4% of total sample isolates, followed by 
Pseudomonas aeruginosa(12.1%). From the study findings, 44.8% of total sample 
was isolated from sputum cultures (table 1). 
Table 1. Distribution of Study variables 
variable Level of variable Frequency Percent 
Culture 
Result 
I 68 7.3 
R 580 62.6 
S 279 30.1 
Total 927 100.0 
 
Sex 
 
M 287 31.0 
F 640 69.0 
Total 927 100.0 
 
Age order 
1-20 years 124 13.4 
21-40 years 213 23.0 
41-60 years 261 28.2 
 60 329 35.5 
Total 927 100.0 
 
 
 
 
Type of 
bacteria 
Acinetobacterbaumannii 24 2.6 
Acinetobacter species 185 20.0 
Alpha Hemolytic Streptococcus 2 0.2 
B-Hemolytic Streptococcus-Group-A 1 0.1 
B-Hemolytic Streptococcus-Group-D 1 0.1 
CitrobacterSpp 5 0.5 
Coagulase negative Staphylococci 57 6.1 
EnterobacterSpp 3 0.3 
Enterococcus Spp 19 2.0 
Escherichia coli 226 24.4 
Klebsiellapneumoniae 99 10.7 
KlebsiellaSpp 50 5.4 
Moraxella Spp 4 .4 
Methicillin Resistant Staphylococcus 
aureus(MRSA) 
17 1.8 
Neisseria Spp 1 0.1 
Nocardia SPP 1 0.1 
Proteus mirabilis 3 0.3 
Proteus Spp 10 1.1 
Proteus vulgaris 1 0.1 
Pseudomonas aeruginosa 112 12.1 
SerratiaSpp 4 0.4 
Staphylococcus aureus 72 7.8 
Streptococcus pneumoniae 3 .3 
Streptococcus spp. 27 2.9 
Total 927 100.0 
 
 
 
Aspirated Fluid Culture 1 0.1 
Blood Culture 22 2.4 
Cerepro Spinal Fluid ( CSF ) C/S 144 15.5 
  
Type of  
sample 
General swab for Culture 17 1.8 
Pleural Fluid For Culture & 
Sensitivity 
27 2.9 
Ascitic fluid c/s and sensitivity 6 0.6 
Pus For Culture & Sensitivity 91 9.8 
Sputum Culture 415 44.8 
Throat swab Culture 1 0.1 
Urine Culture 120 12.9 
Wound Swab  For Culture 83 9.0 
Total 927 100.0 
 
 
Figure 1. Distribution of Moxifloxacin Susceptibility among Study Sample 
Results in table 3 indicated that the relationship between bacteria type and culture 
results was statistically significant (P-value < 0.001).In the present study, 96.2% of 
Acinetobacter species were moxifloxacin resistant and all Acinetobacterbaumannii 
isolates were moxifloxacin resistant. Also the study findings reported that 70.4% of 
Escherichia coliisolates were resistant for moxifloaxin,followed by 
Klebsiellapneumonia (60.6%),methicillin resistant staphylococcus aureus 
(64.7%),pseudomonas aeruginosa (46.4%). However,86.1% of staphylococcus aureus 
isolates weremoxifloxacin resistant. 
Table 2. Distribution of bacteria type according to culture results 
 
Type of Bacteria 
Culture Result  
Total 
 
P-value I R S 
Acinetobacterbaumannii 0 24 0 24  
 
 
 
 
 
 
 
 
 
 
 
Acinetobacter species 2 177 6 185 
Alpha Hemolytic Streptococcus 0 1 1 2 
B-Hemolytic Streptococcus-Group-A 0 1 0 1 
B-Hemolytic Streptococcus-Group-D 0 1 0 1 
CitrobacterSpp 2 1 2 5 
Coagulase negative Staphylococci 19 14 24 57 
EnterobacterSpp 2 0 1 3 
Enterococcus Spp 0 18 1 19 
Escherichia coli 7 159 60 226 
Klebsiellapneumoniae 10 60 29 99 
KlebsiellaSpp 2 42 6 50 
  
There wasnot statistically significant difference between culture resultswith sex (P-
value= 0.25). However, there was a statistically significant difference between culture 
results with age groups (P-value = 0.02). Also 64.1% of 
maleshadmoxifloxacinresistant and 36.9% of isolate resistantwere aged >60 years 
(table 3). 
Table 3. Distribution of age group and sex according to Culture results  
 
Variable 
Culture results  
Total 
 
P-value 
I R   S 
Sex 
F 26 170 91 287  
0.25 
 
M 42 410 188 640 
Total 68 580 279 927 
Age group 
Less 20 14 62 48 124  
 
0.02 
21-40 12 134 67 213 
41-60 13 170 78 261 
 60 29 214 86 329 
Total 68 580 279 927 
 
Figure 2. Distribution of age group and sex according to Culture results  
Moraxella Spp 0 0 4 4  
 
0.001 
Methicillin Resistant Staphylococcus aureus(MRSA) 6 11 0 17 
Neisseria Spp 0 0 1 1 
Nocardia SPP 0 0 1 1 
Proteus mirabilis 0 3 0 3 
Proteus Spp 2 6 2 10 
Proteus vulgaris 0 0 1 1 
Pseudomonas aeruginosa 11 52 49 112 
SerratiaSpp 0 0 4 4 
Staphylococcus aureus 3 7 62 72 
Streptococcus pneumoniae 0 0 3 3 
Streptococcus spp. 2 3 22 27 
Total 68 580 279 927 
 The relationship between culture results and sample type was analyzed in the table 4.  
Results in this table showed that there was high significantly relationship (P-
value<0.001).  Also 44.8% of sample isolates were from sputum cultures. Moreover, 
74.2% of sputum cultures isolates were moxifloxacin resistant.  
Table 4. Distribution of culture results according to sample type   
 
Sample Type 
Culture Result  
Total 
 
P-value I R S 
Ascitic fluid c/s and sensitivity 0 0 1 1  
 
 
 
 
0.001 
Aspirated Fluid Culture 0 8 14 22 
Blood Culture 18 62 64 144 
Cerepro Spinal Fluid ( CSF ) C/S 0 14 3 17 
General swab for Culture 2 18 7 27 
Pleural Fluid For Culture & Sensitivity 0 1 5 6 
Pus For Culture & Sensitivity 6 31 54 91 
Sputum Culture 28 308 79 415 
Throat swab Culture 0 0 1 1 
Urine Culture 7 83 30 120 
Wound Swab  For Culture 7 55 21 83 
Total 68 580 279 927  
 
 
 
Discussion: 
The primary objective in the development of moxifloxacin was to produce an 
appropriate spectrum antibiotic for the treatment of community-acquired RTIs with a 
good tolerability profile, good efficacy against the relevant pathogens, and low 
propensity for the development of bacterial resistance, thus benefiting patients and 
helping clinicians to treat these diseases
[10]
. 
An effective new antimicrobial agent is necessary in light of the therapeutic problems 
posed by the increasing prevalence of antibiotic resistance of the common respiratory 
tract pathogens, which have become increasingly resistant to traditional first-line 
antibiotics such as penicillins and macrolides
[11]
. 
According to study results, 62.6% of study sample were moxifloxacinresistant isolates 
and only 30.1% were sensitive.   
Moxifloxacin treatment failure is being increasingly reported, particularly in the Asia-
Pacific region along with increasing detection rates of resistance mutations
[12]
. 
Fluoroquinolone resistance is rare in North America.Surveillance studies in the 
United States from 1987 to2009 demonstrated low rates of resistance to moxifloxacin 
(0.1%)
[13]
. Similarly,the prevalence of fluoroquinolone resistance in Canadaremained 
low from 1998 to 2009. Although total per capitaoutpatient use of fluoroquinolones 
increased during this10-year period, levofloxacin and moxifloxacin 
resistanceremained unchanged at <2% in the >26,000 isolates collected
[14]
. 
In contrast to study findings in Pakistan, the prevalence of Moxifloxacin resistant was 
42.4%
[15]
.From the present study findings, 44.8% of total sample was isolated from 
sputum cultures. Moreover, 74.2% of sputum cultures isolates were moxifloxacin 
resistant. The increasing resistance to antibiotics by respiratory pathogens has 
complicated the use of empirical treatment with traditional agents and a definitive 
bacteriological diagnosis and susceptibility testing wouldbe required for effective 
management of LRTI
[16]
.The study findings reported that 70.4% of Escherichia coli 
 
isolates were resistant for moxifloaxin, followed MRSA (64.7%), Klebsiella pneumonia 
(60.6%), and Pseudomonas aeruginosa (46.4%). Also results in this study showed that t there 
was a statistically significant difference between culture results with age groups and 36.9% of 
patients with moxifloxacin resistant isolates were aged > 60 years. 
During the last several years, resistance to fluoroquinoloneshas remained very high 
among MRSA, P. aeruginosaandin pathogens isolated from intensivecare unit-
patients. In addition, the recent reports ofan overall increase in resistance to 
fluoroquinolones amongbacteria causing community-acquired infections, such as 
E.colihave a major concern in clinical practice. These surveillance data 
demonstratethat fluoroquinolone resistance has to be associated with bothparticular 
bacterial species and patientpopulations
[13]
. 
Conclusion and Recommendation: 
LRTIs comprise a wide range of diseases from acute bronchitis to severe pneumonia 
leading to death. This study reveals that varieties of pathogens are responsible for 
LRTI and moxifloxacin resistance has become a great public health issue.The 
possibility ofreducing resistance by controlling the use of antibioticsis a reasonable 
approach. Inappropriate and irrationaldrug usage should be avoided.This study may 
help thegovernment’s regulatory authority to develop a policyabout rational 
prescription of antibiotics to minimizeresistance of new antibiotics and also to ensure 
themaximum safety to the health of patients. 
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